Exchange: NASDAQ·Updated 07:30 PM EST

OCUL News

News
all
press releases
Ocular Therapeutix Grants Inducement Stock Awards To Tiffany Howard
(RTTNews) - On Friday, Ocular Therapeutix, Inc. (OCUL) granted inducement stock awards to Tiffany Howard, its newly appointed Executive Vice President of Commercial Retina, under its 2019 Inducement Stock Incentive Plan, in connection with her joining the company and in complianc...
Nasdaq News: Markets
Ocular Therapeutix Grants Inducement Stock Awards To Tiffany Howard
(RTTNews) - On Friday, Ocular Therapeutix, Inc. (OCUL) granted inducement stock awards to Tiffany Howard, its newly appointed Executive Vice President of Commercial Retina, under its 2019 Inducement Stock Incentive Plan, in connection with her joining the company and in complianc...
Nasdaq News: Markets
More News
Ocular Therapeutix (NASDAQ:OCUL) Sets New 12-Month Low - Here's What Happened...
MarketBeat
Ocular Therapeutix, Inc. (OCUL) Presents at UBS Global Biopharma Conference 2026 Transcript...
SeekingAlpha
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -16.67% and -7.45%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
NewAmsterdam Pharma Company N.V. (NAMS) delivered earnings and revenue surprises of +72.00% and +67.44%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Corcept (CORT) delivered earnings and revenue surprises of +48.53% and +3.43%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Oversold health care stocks Align Technology, Dianthus Therapeutics and Ocular Therapeutix show RSI readings near or below 30, signaling potential value.read more...
Benzinga
Rocket, RegenXBio, Precision BioSciences, Kyverna and uniQure will present on Monday at a cell and gene-therapy conference.
Stocktwits
OCUL stock selloff began on Monday after Kodiak Sciences and 4D Molecular posted updates from clinical trials of their eye-disease drugs.
Stocktwits
OCUL’s selloff on Monday was spurred by clinical updates from competitors on their wet AMD treatments.
Stocktwits

Advertisement|Remove ads.